Evaluating 5ASA efficacy in treatment of symptomatic hemorrhoid

Evaluating 5ASA efficacy in treatment of symptomatic hemorrhoid in non-IBD patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191226045897N2

Enrollment

100

Registered

2021-05-03

Start date

2021-04-29

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemorrhoids. Unspecified haemorrhoids without complication

Interventions

Intervention 1: Intervention group: Common hemorrhoid treatment (including anti-hemorrhoid ointment and laxative treatment) with 5-ASA suppository once a day for 2 weeks. Intervention 2: Control group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Sigmoidoscopy Hemorrhoids based on clinical indicators and examination

Exclusion criteria

Exclusion criteria: Hemorrhoids stage 3 and up Ulcerative proctitis Pregnancy or breastfeeding Allergy to salicylates Liver dysfunction Renal dysfunction

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Pain. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Anal burning. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hassan Abedi

Babol University of Medical Sciences

h.abedi@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026